Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Lumos Pharma in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($4.25) per share for the year.
Shares of Lumos Pharma stock opened at $7.94 on Wednesday. Lumos Pharma has a 12 month low of $6.15 and a 12 month high of $12.05. The stock has a 50 day moving average of $8.32 and a 200 day moving average of $8.38.
Several hedge funds have recently modified their holdings of the stock. PVG Asset Management Corp purchased a new position in Lumos Pharma during the 4th quarter worth $71,000. Envestnet Asset Management Inc. acquired a new stake in Lumos Pharma during the 4th quarter worth about $72,000. Citadel Advisors LLC acquired a new position in shares of Lumos Pharma in the 3rd quarter valued at about $113,000. Millennium Management LLC purchased a new position in shares of Lumos Pharma in the 3rd quarter valued at about $146,000. Finally, Private Advisor Group LLC purchased a new position in shares of Lumos Pharma in the 1st quarter valued at about $263,000. 38.35% of the stock is owned by hedge funds and other institutional investors.
Lumos Pharma Company Profile (Get Rating)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Heavy Buying Points to Upside for These 3 Stocks
- 3 Intriguing Stocks With Sub-10 P/E Ratios
- Time to Buy Take-Two Interactive Stock
- Snap Inc: Revised Guidance & Steeping Losses
- 3 Software Plays Showing Signs of Recovery
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.